Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...
Anish Suri, Ph.D., president & chief scientific officer (CSO) of Cue Biopharma, to transition to principal research and immunology advisor BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.
JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...
Like most major biotech players, Abbvie eyed M&A as a major strategy to build out its pipeline and chart a future. And ...
Baird Small/Mid Cap Growth portfolio increased +6.9% in 3Q, net of fees, compared to the +7.0% increase in our primary ...
Real-time index price for S&P 500 Financials [Sector] (SRFI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...
CAMDEN, N.J., November 11, 2024--(BUSINESS WIRE)--The American Water Charitable Foundation, a 501(c)(3) organization ...
EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...
The energy sector, particularly midstream companies, is set to benefit from Trump's pro-oil and gas policies, boosting fossil ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback